Program
vixticibart
Its studies are mostly in Heart Failure · Hypertension, led by Regeneron Pharmaceuticals.
Furthest: phase 2, since Apr 25, 20224 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 40 open or running | phase 2since Apr 25, 2022 | Jul 28, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2020First study: phase 1 study in HealthyFirst studyNCT04506645 · 90 enrolled · Belgium
- Apr 25, 2022Phase 2 study in Heart FailureNCT05353166 · 59 enrolled · Moldova
- Jan 23, 2024Phase 2 study in Heart FailureNCT06237309 · 89 enrolled · United States, Belgium, Bulgaria and more
- Feb 12, 2025Phase 2 study in HypertensionNCT06833190 · 34 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06833190Hypertension · United Kingdom | 2 | Terminated | Oct 15, 2025 | 34 |
| NCT06237309Heart Failure · United States, Belgium, Bulgaria and more | 2 | Terminated | Sep 17, 2025 | 89 |
| NCT05353166Heart Failure · Moldova | 2 | Completed | Jun 2, 2025 | 59 |
| NCT04506645Healthy · Belgium | 1 | Completed | Dec 14, 2022 | 90 |
How it is read
Names in the registry
- “REGN5381”, 4 entries
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.